Replimune Group (NASDAQ:REPL) Trading Down 5.2% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL) shares dropped 5.2% during mid-day trading on Monday . The stock traded as low as $8.70 and last traded at $8.98. Approximately 921,331 shares were traded during trading, a decline of 81% from the average daily volume of 4,867,033 shares. The stock had previously closed at $9.47.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on REPL shares. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Wedbush upped their target price on shares of Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a research note on Monday, June 1st. Jefferies Financial Group restated a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Finally, Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Seven investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Replimune Group has an average rating of “Reduce” and an average price target of $4.88.

Replimune Group Stock Down 7.1%

The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $726.23 million, a P/E ratio of -2.56 and a beta of 0.91. The stock’s 50 day simple moving average is $5.11 and its 200 day simple moving average is $7.27.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This represents a 6.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC bought a new position in Replimune Group during the 4th quarter valued at $29,000. Russell Investments Group Ltd. boosted its stake in Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after acquiring an additional 7,569 shares during the last quarter. CWM LLC boosted its stake in Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. Essential Partners LLC boosted its stake in Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after acquiring an additional 6,873 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.